Trial Profile
Post-Marketing Surveillance(PMS) of Safety and Efficacy of Samsca Tablets in Korean Patients With ADPKD
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Oct 2023
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Renal failure
- Focus Adverse reactions
- Sponsors Korea Otsuka Pharmaceutical
- 12 Nov 2019 Planned End Date changed from 1 Nov 2019 to 1 Nov 2025.
- 12 Nov 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Nov 2025.
- 25 Jan 2018 New trial record